Guselkumab
- Generic Name
- Guselkumab
- Brand Names
- Tremfya
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1350289-85-8
- Unique Ingredient Identifier
- 089658A12D
- Background
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptoma...
- Indication
Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Janssen-Cilag S.p.A.
- Target Recruit Count
- 356
- Registration Number
- NCT04439526
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria - OO.RR. San Giovanni di Dio Ruggi d'Aragona, Cava de' Tirreni, Italy
🇮🇹Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli, Napoli, Italy
🇮🇹Ospedale San Giovanni di Dio, Cagliari, Italy
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 38
- Registration Number
- NCT04397263
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital, Bunkyo ku, Japan
🇯🇵KOKIKAI Tokatsu Tsujinaka Hospital, Abiko, Japan
🇯🇵Hitachi General Hospital, Hitachi, Japan
An Explorative Psoriasis Biomarker Study
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Centre for Human Drug Research, Netherlands
- Target Recruit Count
- 50
- Registration Number
- NCT04394936
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
🇳🇱Máxima Medisch Centrum, Veldhoven, Netherlands
A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 440
- Registration Number
- NCT04147338
- Locations
- 🇩🇪
CRS Clinical Research Services, Mannheim, Germany
🇺🇸Celerion, Tempe, Arizona, United States
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- Rockefeller University
- Registration Number
- NCT04084665
- Locations
- 🇺🇸
Rockefeller Unviersity, New York, New York, United States
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1064
- Registration Number
- NCT04033445
- Locations
- 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇵🇹Uls Sao Joao - Hosp. Sao Joao, Porto, Portugal
🇺🇸Univ. of South Florida Med. Group, Tampa, Florida, United States
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 880
- Registration Number
- NCT03818035
- Locations
- 🇩🇪
MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany
🇩🇪Universitatsklinikum Dusseldorf, Düsseldorf, Germany
🇫🇷Hopital Prive d'Antony, Antony, France
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT03649971
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1027
- Registration Number
- NCT03573323
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Arlington Research Center, Inc, Arlington, Texas, United States
🇺🇸Dermatology Clinical Trials, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.